Form 8-K - Current report

0001287098false00012870982024-11-062024-11-06

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 6, 2024

​

​

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-40674		52-2210438
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

​

[phone]

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value	​	MXCT	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company    ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On November 6, 2024, MaxCyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

​

​

​

Item 7.01. Regulation FD Disclosure.

​

On November 6, 2024, the Company posted an updated corporate presentation, which the Company may use from time to time in communications or conferences, to its website at https://investors.maxcyte.com.  A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in this Current Report on Form 8-K, including Exhibit 99.2 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

Exhibit Number		Exhibit Description
​	​	​
99.1	​	Press Release, dated November 6, 2024
99.2	​	Corporate Presentation, dated November 2024
104	​	Cover Page Interactive Data (embedded within the Inline XBRL document)

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	MaxCyte, Inc.
​	​
Dated: November 6, 2024	By:	/s/ Douglas Swirsky
​	​	Douglas Swirsky
​	​	Chief Financial Officer

​

​

​

Exhibit 99.1

​

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance.

Third Quarter and Recent Highlights

●

Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over the third quarter of 2023.

●

Core business revenue of $8.1 million in the third quarter of 2024, an increase of 23% over the third quarter of 2023.

●

No material Strategic Platform License (SPL) Program-related revenue was recorded in the third quarter of 2024, consistent with the Company’s expectations which reflected $6.0 million in SPL program-related revenue received during the first two quarters of 2024.

●

Six new SPL clients signed year-to-date. Kamau Therapeutics signed in September, Legend Biotech signed in May, Be Biopharma signed in March, and Wugen, Imugene, and Lion TCR signed in January. The total number of SPL partners now stands at 29.

●

Total cash, cash equivalents and investments were $196.6 million as of September 30, 2024.

“I am pleased with MaxCyte’s financial performance in the third quarter, and confident in our outlook for the remainder of 2024. We believe our strong core revenue growth and increasing demand for our platform was driven by exceptional commercial execution, and the value proposition that MaxCyte holds within the cell therapy industry. Coming out of a difficult 2023, this year we have consistently delivered with three strong quarters of core revenue, along with disciplined operational execution allowing us to maintain our healthy cash balance sheet,” said Maher Masoud, President and CEO at MaxCyte.

“So far in 2024, we have signed 6 new SPLs, which represents a record number of new SPL clients in a single year for MaxCyte. Our most recently signed SPL, Kamau Therapeutics, brings our total number of SPLs to 29. We are very excited by our customers’ progress on their programs and remain focused on providing them with the best support possible in their development efforts. As we expand our technology to more customers and programs, the ExPERT Platform supports a growing number of technologies requiring multiple edits and steps, as well as therapies in a range of new indications.”

In addition to growing revenue, MaxCyte continues to prioritize its investments towards those that it believes will provide the best return on investment and long-term growth. The Company is also continuously evaluating and executing on opportunities to reduce its cost structure and improve operational focus and efficiency. As part of these efforts, the Company is considering the costs and benefits of maintaining dual listings on AIM and Nasdaq. A potential cancellation of the admission of its common stock from trading on AIM would allow the Company to concentrate its efforts exclusively on the NASDAQ exchange, where the vast majority of its trading volume now occurs. Concentrating trading

​

1

---

on a single exchange is expected to improve liquidity and reduce the administrative costs associated with maintaining dual listings. The Board is contemplating requesting shareholder approval to implement this strategy at the 2025 Annual Meeting of Shareholders, although no decision has been taken by the Board at this time in respect of any such cancellation from admission to trading on AIM. The Company anticipates that the 2025 Annual Meeting will be held between May and July 2025, subject to the filing of a proxy statement with the Securities and Exchange Commission.

The following table provides details regarding the sources of the Company’s revenue for the periods presented.

	​	​	​	​	​	​	​	​
​		Three Months Ended						​
​	​	September 30, (Unaudited)					​	​
​		2024			2023			%
(in thousands, except percentages)	​	​	​	​	​	​	​	​
Cell therapy	​	$	6,511	​	$	4,700	​	39%
Drug discovery	​	​	1,629	​	​	1,900	​	(14%)
Program-related	​	​	24	​	​	1,404	​	(98%)
Total revenue	​	$	8,164	​	$	8,004	​	2%

​

	​	​	​	​	​	​	​	​
​		Three Months Ended						​
​	​	September 30 (Unaudited)					​	​
​		2024			2023			%
(in thousands, except percentages)	​	​	​	​	​	​	​	​
Instrument	​	$	1,764	​	$	1,672	​	6%
PAs	​	​	3,432	​	​	2,226	​	54%
Lease	​	​	2,528	​	​	2,444	​	3%
Other	​	​	416	​	​	258	​	61%
Total Core Revenue	​	$	8,140	​	$	6,600	​	23%

​

In addition to revenue, management regularly reviews key business metrics to evaluate the business, measure performance, identify trends affecting the business, formulate financial projections and make strategic decisions. As of the dates presented, some key metrics were as follows:

​

2

---

​

​	​	​	​	​
​	​	Three Months Ended September 30,
​		2024		2023
Installed base of instruments (sold or leased)	​	739	​	664
Core Revenue Generated by SPL Clients as a % of Core Revenue	​	53%	​	45%

​

Third Quarter 2024 Financial Results

Total revenue for the third quarter of 2024 was $8.2 million, compared to $8.0 million in the third quarter of 2023, representing growth of 2%.

Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers, excluding SPL Program-related revenue) for the third quarter of 2024 was $8.1 million, compared to $6.6 million in the third quarter of 2023, representing an increase of 23%.

Cell therapy revenue for the third quarter of 2024 was $6.5 million, compared to $4.7 million in the third quarter of 2023, representing an increase of 39%. Drug discovery revenue for the third quarter of 2024 was $1.6 million, compared to $1.9 million in the third quarter of 2023, representing a decline of 14%.  

SPL Program-related revenue was immaterial in the third quarter of 2024, as compared to $1.4 million in the third quarter of 2023, representing a decrease of 98% over the third quarter of 2023.

Gross profit for the third quarter of 2024 was $6.2 million, compared to $7.2 million in the third quarter of 2023.

Gross margin for the third quarter of 2024 was 76%, compared to gross margin of 90% in the third quarter of 2023. Non-GAAP adjusted gross margin was 85% when excluding SPL program related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 88% in the third quarter of 2023.

Operating expenses for the third quarter of 2024 were $20.3 million, compared to operating expenses of $21.2 million in the third quarter of 2023.

Third quarter 2024 net loss was $11.6 million compared to net loss of $11.3 million for the same period in 2023. EBITDA, a non-GAAP measure, was a loss of $13.0 million for the third quarter of 2024, compared to a loss of $12.9 million for the third quarter of 2023; stock-based compensation expense was $3.4 million in the third quarter of 2024 compared to $3.6 million in the third quarter of 2023.

2024 Revenue Guidance

MaxCyte increases 2024 revenue guidance for core business revenue and affirms SPL Program-related revenue guidance.

​

3

---

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY^TM.

MaxCyte now expects to end 2024 with approximately $185 million in total cash, cash equivalents and investments.

Webcast and Conference Call Details

MaxCyte will host a conference call today, November 6, 2024, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

Non-GAAP Financial Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses this non-GAAP measure to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory.  The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

​

4

---

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements.  Forward-looking statements include, but are not limited to, statements about the Company’s projected full-year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions.  These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following:  our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; our expectation that our partners will have access to capital markets to develop and commercialize their cell therapy programs; our financial performance and capital requirements; the amount and adequacy of our cash resources; and our plans with respect to potential cancellation of the admission of our common stock from trading on the AIM exchange.

These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on or about March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events.

​

5

---

We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.  

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

[phone]

[e-mail]

US Media Relations

Spectrum Science

Jordan Vines

[phone]

[e-mail]

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

[phone]

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

[phone]

[e-mail]

​

6

---

MaxCyte, Inc.

Unaudited Consolidated Balance Sheets

(in thousands, except share and per share amounts)

​	​	​	​	​	​	​
​	​	As of
​		September 30, 2024			December 31, 2023
Assets	​	​	​	​	​	​
Current assets:	​	​	​	​	​	​
Cash and cash equivalents	​	$	36,958	​	$	46,506
Short-term investments, at amortized cost	​	​	116,874	​	​	121,782
Accounts receivable, net	​	​	4,560	​	​	5,778
Inventory	​	​	10,393	​	​	12,229
Prepaid expenses and other current assets	​	​	4,124	​	​	3,899
Total current assets	​	​	172,909	​	​	190,194
​	​	​	​	​	​	​
Investments, non-current, at amortized cost	​	​	42,797	​	​	42,938
Property and equipment, net	​	​	20,967	​	​	23,513
Right-of-use asset - operating leases	​	​	10,888	​	​	11,241
Other assets	​	​	1,051	​	​	388
Total assets	​	$	248,612	​	$	268,274
​	​	​	​	​	​	​
Liabilities and stockholders’ equity	​	​	​	​	​	​
Current liabilities:	​	​	​	​	​	​
Accounts payable	​	$	1,865	​	$	743
Accrued expenses and other	​	​	8,196	​	​	11,269
Operating lease liability, current	​	​	907	​	​	774
Deferred revenue, current portion	​	​	6,653	​	​	5,069
Total current liabilities	​	​	17,621	​	​	17,855
​	​	​	​	​	​	​
Operating lease liability, net of current portion	​	​	17,412	​	​	17,969
Other liabilities	​	​	277	​	​	283
Total liabilities	​	​	35,310	​	​	36,107
​	​	​	​	​	​	​
Commitments and contingencies	​	​	​	​	​	​
Stockholders’ equity	​	​	​	​	​	​
Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2024 and December 31, 2023	​	​	—	​	​	—
Common stock, $0.01 par value; 400,000,000 shares authorized, 105,300,380 and 103,961,670 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	​	​	1,053	​	​	1,040
Additional paid-in capital	​	​	418,505	​	​	406,925
Accumulated deficit	​	​	(206,256)	​	​	(175,798)
Total stockholders’ equity	​	​	213,302	​	​	232,167
Total liabilities and stockholders’ equity	​	$	248,612	​	$	268,274

​

​

7

---

MaxCyte, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share amounts)

​

​

​

​

​

Three Months Ended September 30,

Nine Months Ended September 30,

​

2024

2023

2024

2023

Revenue

​

$

8,164

​

$

8,004

​

$

29,934

​

$

25,623

Cost of goods sold

​

​

1,928

​

​

793

​

​

4,819

​

​

3,169

Gross profit

​

​

6,236

​

​

7,211

​

​

25,115

​

​

22,454

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Research and development

​

​

5,316

​

​

6,264

​

​

17,613

​

​

17,975

Sales and marketing

​

​

6,207

​

​

7,046

​

​

20,188

​

​

19,778

General and administrative

​

​

7,745

​

​

6,820

​

​

22,487

​

​

21,982

Depreciation and amortization

​

​

1,021

​

​

1,033

​

​

3,123

​

​

2,922

Total operating expenses

​

​

20,289

​

​

21,163

​

​

63,411

​

​

62,657

Operating loss

​

​

(14,053)

​

​

(13,952)

​

​

(38,296)

​

​

(40,203)

​

​

​

​

​

​

​

​

​

​

​

​

​

Other income:

​

​

​

​

​

​

​

​

​

​

​

​

Interest income

​

​

2,496

​

​

2,701

​

​

7,838

​

​

7,558

Total other income

​

​

2,496

​

​

2,701

​

​

7,838

​

​

7,558

Net loss

​

$

(11,557)

​

$

(11,251)

​

$

(30,458)

​

$

(32,645)

Basic and diluted net loss per share

​

$

(0.11)

​

$

(0.11)

​

$

(0.29)

​

$

(0.32)

Weighted average shares outstanding, basic and diluted

​

​

105,109,603

​

​

103,449,715

​

​

104,614,679

​

​

103,121,997

​

​

8

---

MaxCyte, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

​	​	​	​	​	​	​
​	​	Nine months ended September 30,
​		2024			2023
Cash flows from operating activities:	​	​	​	​	​	​
Net loss	​	$	(30,458)	​	$	(32,645)
​	​	​	​	​	​	​
Adjustments to reconcile net loss to net cash used in operating activities:	​	​	​	​	​	​
Depreciation and amortization	​	​	3,258	​	​	3,069
Non-cash lease expense	​	​	353	​	​	286
Net book value of consigned equipment sold	​	​	35	​	​	80
Loss on disposal of fixed assets	​	​	462	​	​	2
Stock-based compensation	​	​	9,949	​	​	10,405
Credit loss (recovery) expense	​	​	(130)	​	​	221
Change in excess/obsolete inventory reserve	​	​	834	​	​	—
Amortization of discounts on investments	​	​	(5,052)	​	​	(5,123)
​	​	​	​	​	​	​
Changes in operating assets and liabilities:	​	​	​	​	​	​
Accounts receivable	​	​	1,348	​	​	3,571
Accounts receivable - TIA	​	​	—	​	​	1,912
Inventory	​	​	835	​	​	(4,088)
Prepaid expense and other current assets	​	​	(225)	​	​	(924)
Other assets	​	​	(732)	​	​	190
Accounts payable, accrued expenses and other	​	​	(1,420)	​	​	1,520
Operating lease liability	​	​	(424)	​	​	(13)
Deferred revenue	​	​	1,584	​	​	(1,127)
Other liabilities	​	​	(6)	​	​	(3)
Net cash used in operating activities	​	​	(19,789)	​	​	(22,667)
​	​	​	​	​	​	​
Cash flows from investing activities:	​	​	​	​	​	​
Purchases of investments	​	​	(118,339)	​	​	(185,621)
Maturities of investments	​	​	128,440	​	​	247,520
Purchases of property and equipment	​	​	(1,504)	​	​	(2,785)
Proceeds from sale of equipment	​	​	—	​	​	9
Net cash provided by investing activities	​	​	8,597	​	​	59,123
​	​	​	​	​	​	​
Cash flows from financing activities:	​	​	​	​	​	​
Proceeds from exercise of stock options	​	​	1,379	​	​	1,650
Proceeds from issuance of common stock under employee stock purchase plan	​	​	265	​	​	—
Net cash provided by financing activities	​	​	1,644	​	​	1,650
Net (decrease) increase in cash and cash equivalents	​	​	(9,548)	​	​	38,106
Cash and cash equivalents, beginning of period	​	​	46,506	​	​	11,064
Cash and cash equivalents, end of period	​	$	36,958	​	$	49,170

​

​

9

---

Unaudited Reconciliation of Net Loss to EBITDA

(in thousands)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

Nine Months Ended

​

​

September 30,

​

September 30,

​

2024

2023

2024

2023

Net loss

​

$

(11,557)

​

$

(11,251)

​

$

(30,458)

​

$

(32,645)

Depreciation and amortization expense

​

​

1,066

​

​

1,081

​

​

3,258

​

​

3,069

Interest income

​

​

(2,496)

​

​

(2,701)

​

​

(7,838)

​

​

(7,558)

Income taxes

​

​

—

​

​

—

​

​

—

​

​

—

EBITDA

​

$

(12,987)

​

$

(12,871)

​

$

(35,038)

​

$

(37,134)

​

​

10

---

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin

(in thousands, except for percentages)

​

​

​

​

​

​

​

​

Three months ended September 30, 2024

Three months ended September 30, 2023

​

​

GAAP

​

Adjustments

​

Non-GAAP

​

GAAP

​

Adjustments

​

Non-GAAP

Revenue

​

$

8,164

​

$

(24)

​

$

8,140

​

$

8,004

​

$

(1,404)

​

$

6,600

Cost of Goods Sold

​

​

1,928

​

​

(697)

​

​

1,231

​

​

793

​

​

—

​

​

793

Gross Margin

​

$

6,236

​

$

673

​

$

6,909

​

$

7,211

​

$

(1,404)

​

$

5,807

Gross Margin %

​

76%

​

​

​

85%

​

​

90%

​

​

​

​

​

88%

​

11

---

Exhibit 99.2

® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT November 2024

2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individual or organization to a significant risk of losing all of their investment. If you are in any doubt about the investment to which this Presentation relates, you should consult a person authorized by the Financial Conduct Authority who specializes in advising on securities of the kind described in this Presentation or your stockbroker, bank manager, solicitor, accountant or other financial adviser. This Presentation has been issued by MaxCyte Inc (the “Company”) and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities in the Company in any jurisdiction. Neither this Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in any connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any such securities. This Presentation does not constitute a recommendation regarding the securities of the Company. This Presentation is only addressed to and directed at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (iii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and/or (iv) any other persons to whom this Presentation may otherwise lawfully be communicated without contravention of section 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This Presentation may not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this Presentation relates is available only to relevant persons. Certain statements in this Presentation are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding our expected potential future revenue. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Presentation, including, without limitation, statements regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, our quarterly reports for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available on the Securities and Exchange Commission website and through the Investor Menu, Financials section under "SEC filings" on the Investors page of our website at http://investors.maxcyte.com. No statement in this Presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements. Any forward-looking statements represent our views only as of the date of this Presentation and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. This Presentation also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability. Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin is included in the appendix of this release. © 2024 MaxCyte, Inc. All Rights Reserved

With 739 platforms in place*, our proprietary technology unlocks the significant potential of advanced therapeutics Leading the growing next-generation cell therapy market and capitalizing on rising demand for non-viral engineering approaches Innovative business model focused on value creation and shared partnership success • Extensive product portfolio, supported by 150 granted U.S. and foreign patents • Total revenue of $8.2 million in third quarter 2024, and core revenue of $8.1 million • Gross profit $6.2 million in third quarter of 2024, representing gross margin of ~76%, non-GAAP adjusted gross margin** of ~85% • Total cash, cash equivalents and investments were $196.6 million as of September 30, 2024 • 20+ years of cell engineering expertise; 36+ field sales and application scientists that support our customers* • Enables delivery of almost any molecule into almost any cell type • Leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale) • FDA Master File and International Technical Files provide clear regulatory path, potentially reducing clinical risk/shortening clinical development • Used to manufacture drug products for over 60 clinical trials to date • Allows MaxCyte to participate in the value created by our partners’ programs • 29 SPL partnerships, which include approximately $2B in potential pre-commercial milestone payments with upside from commercial sales-based payments • Focused over the long-term on creating a diverse portfolio of patient treatments for indications developed by our strategic partners A Leading Provider of Cell-Engineering Platform Technologies 3 © 2024 MaxCyte, Inc. All Rights Reserved *As of September 30, 2024 **Non-GAAP adjusted gross margin in the quarter excludes SPL Program-related revenue and reserves for excess and obsolete inventory

Who We Are - Collaborative, Innovative and Experienced Partner Impact 29 SPL Partnerships Signed Since 2017 143 Employees* 36+ Field Sales and Application Scientists* Scientific Foundation 1999 2000 Scalable GTx ® Transfection System 2002 FDA Master File 2008 Scalable STx® Transfection System 2018 ATx® Gen 2 Transfection System Drug Discovery Cell Therapy 2021 Listing Nasdaq MXCT July 2021 2016 Listing London Stock Exchange/AIM LSE: MXCT, MXCN March 2016 2019 ExPERT Platform Launch of ExPERT VLx / Grand Opening Rockville, MD 2022 4 2023 First MaxCyte-Enabled Approved Therapy © 2024 MaxCyte, Inc. All Rights Reserved *As of December 31, 2023

ExPERT Platform Addresses Industry Challenges MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster Flow Electroporation® technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review ExPERT platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production Challenges MaxCyte’s Solutions 5 Lack of industry standard for process design causes development to be costly and inconsistent across manufacturing runs © 2024 MaxCyte, Inc. All Rights Reserved

Accelerate Product Development Shared Momentum Unparalleled Support Streamlined Regulatory Process Stable Supply Chain Clinically-Validated Platform Partnering with MaxCyte 6 © 2024 MaxCyte, Inc. All Rights Reserved

MaxCyte: Leading Partner for Complex Cellular Engineering 29 Strategic Platform Licenses (SPL), including 5 in 2023 and 6 in 2024 1 Commercial Program* 29 Signed SPLs 160+ Programs* Clinical Licenses that are part of our SPLs 16 Programs are currently in clinical development * Cleared INDs or Equivalent *Updated as of December 31, 2023 7 Lyell Immunopharma Sana Biotechnology Beam Therapeutics © 2024 MaxCyte, Inc. All Rights Reserved

Value Creation from SPLs Licensing deals include significant development milestones and high-value participation in future commercial success of partners Potential value of pre-commercial (clinical development) milestones from SPLs: ~$2B Sales-based payments upon partner’s product commercialization Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success Milestone revenue is MaxCyte’s highest growth revenue stream **Casebia/CRISPR’s SPL partnership (signed in 2017) included the rights to use MaxCyte’s technology in the development of exa-cel (formerly known as CTX001). As announced in the press release on September 28th, 2022, Vertex has signed an SPL agreement with MaxCyte – Vertex has obtained the clinical and commercial rights to use MaxCyte’s technology for the development of exa-cel (formerly known as CTX001). Potential Value of Pre-Commercial Milestones: ~$2B USD Graph is provided for illustrative purposes only. Cumulative Potential Pre-CML Milestones ** ** 2017 2018 2019 2020 2021 2022 2023 8 Lyell Immunopharma Sana Biotechnology 2024 Beam Therapeutics © 2024 MaxCyte, Inc. All Rights Reserved

Instruments and Processing Assemblies Milestones Sales-Based Payments Cell Therapy Partner Program Value Schematic Early Clinical: (Phase 1/2) Years 1-3 Mid-6-figure to Low-7-figure milestones 1-3+ instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ 7-figure milestone per product increasing instrument and disposables usage Approval: Year 5+ Multiple 7-figure milestones Commercial Phase Low single digit % share of sales, including sales-based payments, annual instrument fees and disposable sales Example: Typical Single-Product Revenues from a Representative License Deal 9 © 2024 MaxCyte, Inc. All Rights Reserved

SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial Higher Value Partnership Value Influencing Factors: • Large indications – greater royalty revenues or early achievement of sales-based milestones • Instrument & consumables – Higher utilization Significant upside in commercial revenue opportunity Lower Value Partnership Value Influencing Factors: • Small indications – lower sales royalties or longer time period to realize commercial milestones • Conservative commercial milestones – Smaller opportunity • Instrument & consumables – Lower utilization Lower-bound estimate per Partnership Numbers are illustrative as an example and not specific to one SPL Partnership Example Partnerships Value to MaxCyte* 10 While pre-commercial revenues are comparable, commercial revenues can vary significantly © 2024 MaxCyte, Inc. All Rights Reserved ** *10-year Value to MaxCyte **Weighted based on the expected split of commercial programs in Year 6 (assuming earliest approval); Assumes first 5-years of standard ten-year biotech sales curve

MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity First Wave 1 Approved Partner Program Launched: 2023 SPL Program: Vertex’s Exa-Cel Indications: Sickle Cell Disease Beta-Thalassemia Second Wave 5 Potential Approved Partner Programs Launch Potential: 2026-2027 Indications: Lymphoma/Leukemia Sickle Cell Disease Beta-Thalassemia Third Wave 10 Potential Approved Partner Programs Launch Potential: 2028-2030 Example Indications: Solid Tumors Lymphoma/Leukemia Multiple Myeloma Sickle Cell Disease Beta-Thalassemia Autoimmune Diseases Fourth Wave Additional Preclinical Partner Programs Launch Potential: 2030+ Example Indications: Solid Tumors Autoimmune Diseases Neurodegenerative Diseases Genetic Diseases Lymphoma/Leukemia Fifth Wave Additional Licensed Programs and New Partnerships Signed Launch Potential: 2032+ 11 Source: Evaluate Pharma as of August 5, 2024 © 2024 MaxCyte, Inc. All Rights Reserved

MaxCyte-Enabled Active Clinical Trials 12 00 Allogeneic Autologous Cell Approach: Phase 1 Phase 1/2 Pivotal Commercial Clinical Phase: As of March 2024 / Includes Commercial and Academic Clinical Trials HSCs Other Cell Types APN401 (Invios GmbH) EDIT301: SCD (Editas Med) EDIT301: B-thal Trem-cel (Editas Med) (Vor Biopharma) CB010 (Caribou Biosciences) HSCs T-cells CASGEVYTM for SCD and B-thal (Vertex Pharmaceuticals) T-cells CTX112 (CRISPR Therapeutics) CTX131 (CRISPR Therapeutics) KSQ-001EX (KSQ Therapeutics) Azer-Cel (Imugene) VIPER-101 (Vittoria Biotherapeutics) © 2024 MaxCyte, Inc. All Rights Reserved

13 First MaxCyte-Enabled Therapy is Approved CASGEVYTM for Sickle Cell Disease and for Beta-Thalassemia (2023/2024) MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases Gene-Editing Tools used in MaxCyte-Enabled Clinical Trials Indications in Active MaxCyte-Enabled Clinical Trials Clinical trial = FDA IND clearance or equivalent Hematological Malignancies Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Multiple Myeloma Non-Hodgkin Lymphoma T Cell Lymphoma Autoimmune Diseases Lupus Nephritis ANCA-associated vasculitis Other autoimmune diseases • ARCUS • Base-editing (CRISPR) • CRISPR • RNA-Based Engineering • TALENS • Zinc Finger Nucleases (ZFNs) As of March 2024 / Includes Commercial and Academic Clinical Trials. Source: clinicaltrials.gov Genetic Diseases Beta-Thalassemia Sickle Cell Disease Chronic Granulomatous Disease (CGD) Solid Tumors Non-small Cell Lung Cancer Head and Neck Cancer Glioblastoma Renal Cell Carcinoma Melanoma Other Solid Tumors Infectious Disease HIV © 2024 MaxCyte, Inc. All Rights Reserved

The ExPERT Platform Enabling Non-Viral Cell Engineering • Launched in 2019 based on MaxCyte’s proprietary Flow Electroporation® technology and has been optimized for the past 20+ years • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delivers molecules, such as nucleic acids, gene-editing tools and proteins, into cells • Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology • Enables customers to use a single platform from concept through to the clinic in a GMP environment • Supported by a robust intellectual property portfolio (200+ patents granted in US and foreign jurisdictions and 100+ patents pending worldwide) High Performance: • >90% transfection efficiencies (depending on cell type and molecule) • >90% cell viabilities • Computer-controlled system for reproducible results ExPERT Instrument Portfolio Full scale RUO Small/mid-scale RUO Large Scale RUO/cGMP Flexibility: • Single, fully-defined, animal component-free electroporation buffer for all cell types • Pre-loaded library of validated, cell-specific protocols Scalability – Ability to Transfect: • 75,000 to 7 million cells in seconds • Up to 20 billion cells in less than 30 minutes • And up to 200 billion cells in less than 30 minutes with the high scale VLx High Quality: • Sterile, single-use processing assemblies (PAs) • Closed, cGMP-compliant, ISO-certified, and CE marked instruments • Supported by US FDA Master File and global equivalents Full scale RUO/cGMP 14 © 2024 MaxCyte, Inc. All Rights Reserved

MaxCyte Business Model – Drug Discovery Market Drug Discovery Revenue Model Instrument sale (ATx/STx) Single-use disposables (processing assemblies) Razor/Razor Blade Economics DRUG DISCOVERY & DEVELOPMENT - Cells used to Discover / Produce Drug Products Key Applications: Cell-based assays, protein and antibody production, vaccine development Customer base: Large/small biopharma and academic centers + = 15 Full scale RUO Small/mid-scale RUO © 2024 MaxCyte, Inc. All Rights Reserved

MaxCyte Business Model – Cell Therapy Market Razor/Razor Blade Economics CELL THERAPY – Cell itself is the Drug Key Applications: Ex-Vivo Engineered Cell Therapies Customer Base: Leading global cell therapy developers and academic translational centers + = 16 Full scale RUO Small/mid-scale RUO Preclinical and Academic Revenue Model Instrument Sale (ATx/GTx) Primarily ATx given early development Single-use Disposables (processing assemblies) SPL Partnership Model Full scale cGMP Annual Instrument License Fee (GTx) (Research / Clinical) Razor/Razor Blade Economics and Share of Therapeutic + + = Economics Single-use Disposables (processing assemblies) Strategic Partnership Terms © 2024 MaxCyte, Inc. All Rights Reserved

2023 Summary and 2024 YTD Achievements • Five SPL partnerships announced in 2023: • Prime Medicine in August, Lyell Immunopharma and Vittoria Biotherapeutics in July, Walking Fish Therapeutics in May and Catamaran Bio in January • Douglas J. Swirsky appointed MaxCyte’s Chief Financial Officer, bringing over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations • Published Inaugural ESG 2023 Summary Report in May • First MaxCyte-Enabled Therapy is Approved • Vertex/ CRISPR’s Exa-cel (CASGEVYTM) for Sickle Cell Disease (UK + US) and for Beta-Thalassemia (UK) • Maher Masoud appointed MaxCyte’s President and Chief Executive Officer, bringing more than 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel • Six SPL Partnerships announced in 2024 YTD • Lion TCR to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases • Imugene to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with additional novel cell therapy programs • Wugen - WU-CART-007 lead asset in global Phase 1/2 clinical trial for treatment of relapsed or refractory T-cell lymphoblastic leukemia/lymphoblastic lymphoma • BE Biopharma to support the development of Engineered B Cell Medicines (BCMs) for patients with cancer, rare diseases and other serious conditions • Legend Biotech to advance non-viral engineered cell therapy pipeline across all major regions • Kamau Therapeutics to develop a new class of therapies with the aim to cure a wide range of serious diseases, such as sickle cell disease (SCD) • SPL Partnerships now stands at 29 2023 Achievements 2024 YTD Achievements Prepare/Isolate Concentrate Culture Cryopreserve Thaw/Dose 1 2 3 4 5 6 17 © 2024 MaxCyte, Inc. All Rights Reserved

Thank you! Any questions? [e-mail] 18 © 2024 MaxCyte, Inc. All Rights Reserved

Appendix – Historical Core Business Disclosure 1Q'21 2Q'21 3Q'21 4Q'21 1Q'22 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 3Q’24 (in $ thousands) Cell Therapy 4,729 4,766 6,226 7,263 7,416 7,688 7,897 7,544 5,975 6,637 4,700 5,518 6,415 6,218 6,511 Drug Discovery 1,762 1,838 1,909 2,885 2,167 1,916 1,991 3,026 1,798 1,652 1,900 1,644 1,772 1,357 1,629 Total Core Revenue 6,491 6,604 8,135 10,148 9,583 9,604 9,889 10,570 7,772 8,289 6,600 7,161 8,188 7,575 8,140 Instrument 1,627 1,417 2,517 2,917 2,728 2,697 2,575 3,705 2,189 2,126 1,672 2,330 1,928 1,762 1,764 PAs 2,449 2,624 2,927 4,309 3,840 4,114 4,350 3,721 2,600 3,293 2,226 2,163 3,432 2,974 3,432 Lease 2,252 2,386 2,527 2,643 2,726 2,622 2,736 2,813 2,809 2,667 2,444 2,406 2,604 2,610 2,528 Other 163 177 165 279 290 171 227 331 174 203 258 263 224 229 416 Total Core Revenue 6,491 6,604 8,135 10,148 9,583 9,604 9,889 10,570 7,772 8,289 6,600 7,161 8,188 7,575 8,140 Installed base of instruments (sold or leased) 420 445 472 502 521 546 575 616 633 654 664 683 708 723 739 Core Revenue Generated by SPL Clients as a % of Core Revenue 42% 43% 37% 39% 47% 47% 40% 34% 52% 49% 45% 45% 53% 51% 53%

Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin (in thousands, except for percentages) Three months ended September 30, 2024 Three months ended September 30, 2023 (in $ thousands) GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Revenue $ 8,164 $ (24) $ 8,140 $ 8,004 $ (1,404) $ 6,600 Cost of Goods Sold 1,928 (697) 1,231 793 — 793 Gross Margin $ 6,236 $ 673 $ 6,909 $ 7,211 $ (1,404) $ 5,807 Gross Margin % 76% 85% 90% 88%

Document and Entity Information	Nov. 06, 2024
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Nov. 06, 2024
Entity File Number	001-40674
Entity Registrant Name	MaxCyte, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-2210438
Entity Address State Or Province	MD
Entity Address, Address Line One	9713 Key West Avenue
Entity Address, Adress Line Two	Suite 400
Entity Address, City or Town	Rockville
Entity Address, Postal Zip Code	20850
City Area Code	301
Local Phone Number	944-1700
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MXCT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001287098
Amendment Flag	false
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false

---